GSK Shares Dive as Weaker Vaccine Sales Unnerve Investors

Shares in GSK fell sharply on Wednesday, making the British pharmaceutical company one of the biggest fallers on the FTSE 100, after weaker vaccine sales unsettled investors despite better-than-expected financial results. The decline underscores the sensitivity of GSK's valuation to its vaccines business, which has become a central pillar of the company's growth strategy.

The sell-off came even as the company reported financial results that beat expectations. Investors chose to focus on the softer vaccine revenue, which overshadowed the stronger headline numbers and raised questions about the durability of the company's vaccine-driven earnings.

GSK's position as one of the largest constituents of the FTSE 100 meant the share price drop weighed on the index's performance. The reaction highlights how closely the market is watching the company's vaccine franchise, particularly as it seeks to offset pressure elsewhere in its portfolio.

The divergence between better-than-expected results and a negative share price reaction illustrates the premium investors place on vaccine sales growth. Any sign of weakness in that segment can trigger a sharp reassessment of the company's outlook, even when overall financial performance is solid.

For investors, the move serves as a reminder that headline earnings beats do not always translate into share price gains when a key growth driver disappoints. GSK's vaccine sales trajectory is likely to remain a focal point for the market in the coming quarters, with attention on whether the softer performance is temporary or signals a broader slowdown.